Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (36)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by de Bono, J. S
Right arrow Articles by Rowinsky, E. K
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by de Bono, J. S
Right arrow Articles by Rowinsky, E. K
Related Collections
Right arrow Oncology
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

British Medical Bulletin 64:227-254 (2002)
© 2002 The British Council

Therapeutics targeting signal transduction for patients with colorectal carcinoma

Johann S de Bono* and Eric K Rowinsky*

Institute for Drug Development, Cancer Therapy and Research Center, and University of Texas Health Science Center at San Antonio, Texas, USA

The cytotoxics developed for the treatment of patients with advanced colorectal cancer have yielded diminishing returns. Agents aimed at novel molecular targets are required to improve the prognosis of this disease. This review describes the most recent advances in the clinical development of therapies designed to block the function of several important signalling cellular proteins. Therapies discussed include agents targeting: (i) the epidermal growth factor receptor (EGFR) family; (ii) Ras via the inhibition of farnesyltransferase; (iii) Raf kinase; (iv) the mitogen-activated protein kinase pathway (MAPK, MEK, Erk); (v) Akt; and (vi) the apoptosis signalling pathways including NF-{kappa}B, Bcl-2 and the TRAIL receptor. The results of clinical trials of the first generation of such therapeutics to enter clinical evaluation in malignant diseases are presented. Potential advantages and disadvantages of these different therapeutic modalities are discussed and future challenges for the evaluation of these targeted agents in the clinic is presented.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 CarcinogenesisHome page
R. Hu, T. O. Khor, G. Shen, W.-S. Jeong, V. Hebbar, C. Chen, C. Xu, B. Reddy, K. Chada, and A.-N. T. Kong
Cancer chemoprevention of intestinal polyposis in ApcMin/+ mice by sulforaphane, a natural product derived from cruciferous vegetable
Carcinogenesis, October 1, 2006; 27(10): 2038 - 2046.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Van Schaeybroeck, A. Karaiskou-McCaul, D. Kelly, D. Longley, L. Galligan, E. Van Cutsem, and P. Johnston
Epidermal Growth Factor Receptor Activity Determines Response of Colorectal Cancer Cells to Gefitinib Alone and in Combination with Chemotherapy
Clin. Cancer Res., October 15, 2005; 11(20): 7480 - 7489.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Yokoi and I. J. Fidler
Hypoxia Increases Resistance of Human Pancreatic Cancer Cells to Apoptosis Induced by Gemcitabine
Clin. Cancer Res., April 1, 2004; 10(7): 2299 - 2306.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. P. Carson, N. Zhang, G. M. Frampton, N. P. Gerry, M. E. Lenburg, and M. F. Christman
Pharmacogenomic Identification of Targets for Adjuvant Therapy with the Topoisomerase Poison Camptothecin
Cancer Res., March 15, 2004; 64(6): 2096 - 2104.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Zhang, J. Dai, Z. Yao, Y. Lu, W. Dougall, and E. T. Keller
Soluble Receptor Activator of Nuclear Factor {kappa}B Fc Diminishes Prostate Cancer Progression in Bone
Cancer Res., November 15, 2003; 63(22): 7883 - 7890.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.